|Lead researchers Dr Simon Royce and |
Associate Professor Chrishan Samuel.
A Monash University study co-led by the Central Clinical School’s Dr Simon Royce, which demonstrates that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma, has garnered considerable attention.
Monash scientists provided the experimental expertise to test Cynata Therapeutics' induced pluripotent stem cell-derived mesenchymal stem cells (MSCs) in a model of experimental asthma.
They found that the MSCs could effectively reduce inflammation, reversed signs of airway remodelling and completely normalised airway/lung fibrosis and airway hyperresponsiveness, particularly when delivered intranasally.
Dr Royce is a lecturer in the Department of Medicine at the Alfred Hospital and is part of the Monash Biomedicine Discovery Institute (BDI). He co-led the study with Associate Professor Chrishan Samuel, who heads the Department of Pharmacology’s Fibrosis Laboratory.
The study, which appeared in the FASEB Journal, attracted widespread national and international coverage including EurekAlert!, ScienceDaily, FirstWord, MedTech, labroots, and Medindia.
Read the original press release: